Examining the Beneficial Aspects of Nutritional Guidance Using Estimated Daily Salt Intake in Cancer Patients with Ischemic Heart Disease

19 January 2021: Human Study

Takashi Aoyama ^1ABCDEF* , Takuya Oyakawa ^2B , Akifuimi Notsu ^3C , Emi Oiyama ^4B , Masao Hashimoto ^4B , Reiko Suzuki ^5E , Kei Iida ^6B

DOI: 10.12659/MSMBR.927719

Med Sci Monit Basic Res 2021; 27:e927719

Table 2 Comparison between the improved group and the nonimproved group for estimated daily salt intake*.

	Improved group (n=16)	Nonimproved group (n=11)	P**
Male: Female	12: 4	8: 3	1.00^***

Age, years	74 (63–85)	74 (67–86)	0.80

Assessment period, days	31 (7–111)	43 (21–122)	0.19

BMI, kg/m: T1	24.3 (20.2–32.4)	22.5 (21.5–27.8)	0.52

Bioelectrical impedance analysis

%LBW loss of body weight: T1→T2	−0.2 (−3.0–3.3)	0.0 (−5.3–3.2)	0.94

%LSMM: T1→T2	−0.6 (−20.1–10.1)	1.8 (−14.8–10.2)	1.00

%LFM loss fat mass: T1→T2	1.6 (−24.2–36.8)	6.1 (−11.9–85.1)	0.60

Biochemical examination (blood)

TC rate of change, %: T1→T2	−7.9 (−43.0–17.7)	−6.0 (−32.5–28)	0.69

TG rate of change, %: T1→T2	27.1 (−39.7–101.3)	−40.3 (−60.6–50)

HDL-C rate of change, %: T1→T2	−3.4 (−42.9–37.1)	2.2 (−13.2–27.9)	0.37

Estimated daily salt intake rate of change, %: T1→T2	−25.0 (−75.2––5.4)	12.4 (2.7–173.7)

Stage of cancer	I: 4	I: 6	0.64^***
	II: 5	II: 2
	III: 1	III: 1
	IV: 5	IV: 2
	Unknown site: 1

Cancer site (digestive and nondigestive)	Lung: 5	Stomach: 3	0.39^***
	Colon: 3	Liver: 2
	Prostate: 2	Lung: 2
	Larynx: 2	Colon: 2
	Bladder: 1	Uterus: 1
	Stomach: 1	Thyroid: 1
	Liver: 1
	Esophagus: 1
BMI – body mass index; HDL-C – high-density lipoprotein cholesterol; LBW – loss of body weight; LFM – loss fat mass; LSMM – loss skeletal muscle mass; TC – total cholesterol; TG – triglyceride. ^* The data are expressed as median (range); ^ values are based on Mann-Whitney test unless otherwise noted; ^* value is based on Fisher’s exact test.